Patent portfolios: maximise the value and minimise the cost

According to patent information company IFI Claims, 66% of what it said were the most prolific patenting companies also feature in the Financial Times’stop 500—compelling evidence that research and development (R&D) today creates tomorrow’s successes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Teva faces $500m fine for antitrust breaches over MS drug

Patent portfolios: maximise the value and minimise the cost

Editor's picks

Editor's picks

More features